Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
35 hedge funds and large institutions have $29.3M invested in Cellular Biomedicine Group, Inc. in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
0% less capital invested
Capital invested by funds: $29.4M → $29.3M (-$64.4K)
8% less funds holding
Funds holding: 38 → 35 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$407K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$248K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$164K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$120K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$218K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$209K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$188K |
| 4 |
Barclays
London,
United Kingdom
|
-$79K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$37.6K |
CBMG Hedge Fund Activity: Q4 2018 in Review
35 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2018, worth a combined $29.3M — down 0.22% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CBMG and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 14 added.
The largest buyer was BlackRock, adding an estimated $407K. The largest seller was Deutsche Bank, cutting an estimated $218K.
- 35 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2018, down from 38 in Q3 2018.
- Funds reported $29.3M of Cellular Biomedicine Group, Inc. stock for Q4 2018, down 0.22% quarter-over-quarter.
- 3 funds opened new Cellular Biomedicine Group, Inc. positions in Q4 2018 and 6 closed out, a net change of -3 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2018 was BlackRock, an estimated $407K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2018 was Deutsche Bank, an estimated $218K sold.
Based on aggregated 13F filings for Q4 2018.